Skip to content

Anterior Shoulder Dislocation at Emergency Department

Emergency Department Management of Anterior Shoulder Dislocation Patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06531590
Enrollment
140
Registered
2024-08-01
Start date
2024-03-01
Completion date
2026-03-01
Last updated
2024-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Analgesia, Pain, Shoulder, Shoulder Dislocation

Keywords

shoulder dislocation, interscalene nerve block, suprascapular nerve block, intraarticular lidocaine injection, emergency department

Brief summary

In this study, investigator will analyze the demographic characteristics of patients presenting to emergency department with Anterior Shoulder Dislocation. Investigators will document the mechanism of injury, orthopedic classification of shoulder dislocation, associated treatments, pre-procedural pain scoring, post-procedural pain scoring, as well as the duration of emergency department stay related to the preferred treatment, orthopedic consultation, and patient outcomes (discharge, admission to ward or intensive care unit, mortality). Aim of the study to investigate whether the current treatments used provide any superiority in emergency department outcomes for patients

Detailed description

Intravenous analgesia (Paracetamol, NSAIDs, opioids) is preferred for patients during the treatment and reduction stages of anterior shoulder dislocation. Additionally, patients may receive regional anesthesia and analgesia (lidocaine, bupivacaine). The route and dosage of analgesic administration are chosen by the attending physician managing the patient. In this study, investigators plan to observationally evaluate the analgesic management of patients without intervening in the method and dosage chosen by the primary treating physician. Patients receiving analgesia will be chosen according to preffered treatment at emergency department. The study population will consist of patients presenting to the emergency department with shoulder dislocation who receive analgesia and fall into the following 4 treatment groups. These 4 group will consist in: 1. ketamine group 2. interscalene nerve block group 3. suprascapular nerve block group 4. intraarticular lidocaine injection group. The study will compare these 4 treatment methods in terms of analgesia management, reduction time, comfort, and length of hospital stay for patients presenting to the emergency department with shoulder dislocation and receiving analgesia. The researcher will not interfere with the treatment decision made by the responsible physician or the treatment process

Interventions

None listed

Sponsors

Ankara Etlik City Hospital
CollaboratorOTHER_GOV
Saglik Bilimleri Universitesi
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

Patients aged 18 years and older

Exclusion criteria

Patients who are not conscious at the time of admission and do not consent to participate in the study. Patients who do not have follow-up in our healthcare system or cannot be followed up. Patients with allergies to opioids or local anesthetics. Patients presenting to the emergency department with suspicion of multiple fractures and dislocations involving ≥2 different types of injuries will also be excluded from the study. Forensic cases

Design outcomes

Primary

MeasureTime frameDescription
shoulder reduction24 hourssuccesful reduction of shoulder joint and assessment of pain before and after analgesic treatments with pain scales ( visual analogue scale, verbal pain intensity scale, PAINAD ( pain assessment in advanced dementia) scale andvisual analogue scale)

Countries

Turkey (Türkiye)

Contacts

Primary Contactgulsen akcay, ass. prof.
gulakcay@yahoo.com.tr+905052874949
Backup Contactserife busra uysal, resident
serifebusrauysal@gmail.com+905321131688

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026